Table 3. Prognostic factors for the risk of death in women with invasive breast cancer. Cancer Registry Center, Oncocenter Foundation of São Paulo, 2000–2013.

Variable	Category	HRadj*	95%CI		p
			Lower	Upper
Molecular subtypes	Luminal A	Ref
	Luminal B (HER-2 negative)	1.35	0.91	2.03	0.141
	Luminal B (HER-2 positive)	1.63	0.79	3.40	0.189
	HER-2 positive (nonluminal)	2.30	1.33	3.94	0.003
	Triple-negative	2.51	1.61	3.92	<0.001
Interaction CS at diagnosis and Time between diagnosis and treatment (months)	CS I/II and <2	Ref
	CS I/II and 2 a 4	1.37	0.76	2.46	0.297
	CS I/II and ≥4	1.71	0.97	3.03	0.064
	CS III/IV and <2	3.63	2.21	5.98	<0.001
	CS III/IV and 2 a 4	4.06	2.28	7.22	<0.001
	CS III/IV and ≥4	4.20	2.36	7.49	<0.001

CS: clinical staging. *adjusted by age, year of diagnosis and treatment.